EFRUZHU  19/9 COMPLICATIONS 

SIDE  EFFECTS 

ADVERSE  EFFECTS  

​

®©

​

​

​

1.ALL OF THE  COMPLICATIONS  EXISTENCE  CHEMOTHERAPEUTIC    METABOLIC  ABNORMALITIES   AS  VARIOUS  DEGREE  .

​

2.COMPLICATIONS   ARE PATHOPHYSIOLOGIC  CONDITIONS.

​

3.COMPLICATIONS  DEPENDENCE  ANTICANCER  DRUG  DOSES  AND  ADMINISTRATION  ROUTES.

​

4.COMPLICATIONS  DEPENDENCE OF  CANCER  PATIENT  STAGING.

​

​

5.COMPLICATIONS  RELATED  OF  CANCER  PATIENT  PHARMACOGENETICS  ,PHARMACODYNAMICS  ,PHARMACOKINETICS  PROPERTIES.

​

6.ANTICANCER THERAPEUTIC  MODALITIES    COMPLICATIONS   HAVE  VARIOUS  TOXICITIES.

​

7.ALL OF  THE  COMPLICATIONS  MAIN  ESSENTIAL ORIGINS  ARE   HIGH  LEVEL  OXIDANTS  SO THAT  WILL BE HAPPENED  STRONG  OXIDATIVE  METABOLIC  STRESS.

​

8.ALL OF  THE  COMPLICATIONS  INJURIES  OF  TISSUES/ORGANS  OPPOSE  OF  PHYSIOLOGICAL  PRINCIPLES.

​

9.CHEMOTHERAPY  COMPLICATIONS  DEPENDENCE   OF  STRONG  INFLAMMATIONS.

​

10.CENTRAL  NERVOUS  SYSTEM  CHEMOTHERAPY   COMPLICATIONS  WILL BE  AFFECTED  VITAL/PIVOTAL  CENTERS.

​

11.COMPLICATIONS  OF THE  PULMONAL  ORGAN  TISSUES  PNEUMONITIS  WILL BE  AFFECTED    PH / OXYGENATION  HYPOXIA  AND  BODY  ENERGY  IMBALANCED.

​

12.CARDIAC  TOXICITY  DEGREE/RATE  DIRECTLY  RELATED  CARDIAC  OUTPUT.

​

13.CHEMOTHERAPY  COMPLICATIONS  OF  PERICARDIAL  FLUID  RETENTION AND  CARDIAC  TAMPONADE    RELATED  VARIOUS  FACTORS  AND  MYOCARDIAL  INFARCTION.

​

14.MYOCARDIAL  ISCHEMIA  OF  ANTICANCER   DRUGS  DEPENDENCE  DOSE  AND  INDIVIDUAL  FACTORS.

​

15.CHEMOTHERAPEUTIC  EFFECTS  HYPOTENSION , HYPERTENSION , ENDOCARDIAL  FIBROSIS ETC.  ETHIOLOGIES  AND  COMPLICATIONS RELATED DİRECTLY  OR INDIRECTLY  FACTORS.

​

16.PERICARDIAL  FLUID/EFFUSIONS  SHOULD  BE  MALIGNANT OR  NONMALIGNANT.

​

17.COMPLICATIONSEFFUSIONS  SHOULD BE EXUDATE  OR TRANSUDATE.

​

18.ANTINEOPLASTIC  COMPLICATIONS  EXISTENCE  SYSTOLIC/DIASTOLIC  DYSFUNCTIONS  ,MYOCARDIAL  INJURY  AS  CHEMOTHERAPEUTIC    COMPLICATIONS  SHOULD BE DIAGNOSED WITH TROPONIN,CK ETC.

 

19.CARDIOMYOPATHIE  /CONGESTIVE  HEART  FAILURE  IS THE  FIRST  MAIN  COMPLICATION OF  ANTICANCER  DRUG  TOXICATION.

 

20.CANCER  TREATMENT   SIDE  EFFECTS  DYSRHYTHMIAS(TACHICARDIA-BRADYCARDIA)ARYTHMIAS.

 

21.VARIETY OF  CANCER THERAPIES  AND  VARIOUS  COMBINATIONS OF AGENTS  AND  MODALITIES  SHOULD BE CAUSED   VARIOUS  DEGREE  ADVERSE  EFFECTS.

 

22.ANTINEOPLASTIC  DRUG  COPLICATIONS  SHOULD  BE  REDUCED   CARDIAC  REPAIR,CARDIAC  WORK,WALL STRESS,FREE RADICAL  CAUSED  DAMAGE   AND POOR  PROGNOSIS  OF CANCER PATIENT.

 

23.ANTINEOPLASTIC  DRUG  COMPLICATIONS  MAIN PURPOSE  SHOULD BE RISK  REDUCTION  DOSE/ROUTE/MODALITY  ETC.

 

24.ELECTROLYTE  ABNORMALITIES/IMBALANCE  WILL BE CAUSED  ARRHYTHMIAS  AS  COMPLICATIONS.

 

25.ATRIOVENTRICULAR  BLOCK OF VARYING  DEGREES  HAVE  COMPLICATIONS  OF  CANCER  CHEMOTHERAPY.

 

26.CANCER TREATMENT  WILL BE CAUSED  CORONARY  ARTERY    DISEASE (CORONARY  ATHEROSCLEROSIS)  WITH  OXIDANTS  COMPLICATIONS.

 

27.CHEMOTHERAPYCOMPLICATIONS  THROMBOEMBOLISM , PERIPHERAL  VASCULAR  ISCHEMIA,OCLUSIVE  LESIONS  IN THE  ARTERIES.

 

28.CANCER  PATIENT  THERAPEUTIC  MODALITIES  MAINSTAY  THE OVERALL  RISK-BENEFIT  RATIO  SHOULD  BE  DETECTED  SUCCESS  RATIO  OF  LIFE  QUALITY  AND  LIFE  EXPECTANCY.

​

29.ANTINEOPLASTIC  AGENTS  AND  RADIATION  COMPLICATIONS  EXISTENCE    GENETIC  AND  NONGENETIC  MOLECULAR  DAMAGE.

​

30.CHEMOTHERAPEUTIC  AGENTS  WILL BE  CAUSED   PRODUCED  REACTIVE OXYGEN   SPECIES THAT  CLINICAL  PRESENTATIONS  FEATURES  HISTOPATHOLOGICAL  MOLECULAR,PATHOPHSIOLOGICAL  DESTRUCTION/DAMAGED/INJURIES.

​

31.PULMONARY  TOXICITY  DEGREE  PNEUMONITIS  DEGREE   (PULMONARY  COMPLICATIONS)  RELATED  DIRECTLY  PROPORTIONAL.

​

32.CANCER  THERAPEUTIC  MODALITIES   THE MOST  PREDOMINANT  SYMPTOMS  ARE DYSPNEA AND HYPOXIA,FEVER,COUGH,PLEURITIC  CHEST PAIN,PULMONARY EMBOLISM,INFECTIONS RELATED  IMMUNOSUPPRESSION - METABOLIC  ABNORMALITIES  ,ELECTROLYTE  IMBALANCES,FREE  RADICALS-ROS.

​

33.NEUROTOXICITY  COMPLICATIONS  DEPENDENCE  OF  ANTINEOPLASTIC  AGENTS  OR  RADIATION  SHOULD BE CAUSED  NEUROTOXIC    SYNDROME   THAT ALTERATIONS  NEURONAL METABOLISM  ION  CHANNELS STRUCTURES-MORPHOLOGY  ,CLINICALLY  CANCER  PATIENTS  WITH  NEUROLOGIC  DYSFUNCTION,CEREBELLAR  TOXICITY  ,ENCEPHALOPATHY  ,SPINAL CORD  TOXICITY,PERİPHERAL  NEUROPATHY,CENTRAL  NERVOUS  SYSTEM  TOXICITY,RETINAL TOXICITY,DEMYELINATION  AND  INHIBITION  OF  MYELIN  FORMATION  ETC.  ROUTE  OF  ADMINISTRATION  DOSE,MODALITY  MULTIPLE  COMBINATIONS  THERAPY  OR MONOTHERAPY  AGENTS  REGIMENS  SCHEDULE  AT THE END  SHOULD  HAVE BEEN   GIVEN  US  MESSAGES THAT  SUCCES/  /EXCELLENT / RISK/COMPLICATIONS  BENEFIT  RATIO.